PMID- 17919310
OWN - NLM
STAT- MEDLINE
DCOM- 20071221
LR  - 20201215
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 98
IP  - 12
DP  - 2007 Dec
TI  - Phase I trial of personalized peptide vaccination for cytokine-refractory 
      metastatic renal cell carcinoma patients.
PG  - 1965-8
AB  - The aim of this clinical trial was to investigate the toxicity and immunological 
      responses of personalized peptide vaccination for cytokine-refractory metastatic 
      renal cell carcinoma patients. Patients were confirmed to be human leukocyte 
      antigen (HLA)-A24 or HLA-A2 positive and had histologically confirmed renal cell 
      carcinoma. Ten patients were enrolled in the present study. The peptides to be 
      administered were determined based on the presence of peptide-specific cytotoxic 
      T lymphocyte precursors in peripheral blood mononuclear cells (PBMC) and 
      peptide-specific IgG in the plasma of cancer patients. Patients received 
      subcutaneous injections of four different peptides (3 mg/peptide) every 2 weeks. 
      Vaccinations were well tolerated without any major adverse events. A minimal 
      increase in peptide-specific interferon-gamma production in postvaccination PBMC 
      was observed, regardless of higher levels of cytotoxic T lymphocyte activity in 
      prevaccination PBMC. In contrast, an increase in peptide-specific IgG levels of 
      postvaccination (sixth) plasma was observed in the majority of patients. After 
      progression, five patients received interleukin-2 therapy and continuous 
      vaccination, with survival of 31, 25, 23, 17, and 15 months, but interleukin-2 
      did not impede humoral responses boosted by the vaccination. These results 
      encourage further clinical trials of personalized peptide vaccinations.
FAU - Suekane, Shigetaka
AU  - Suekane S
AD  - Department of Urology, Kurume University School of Medicine, Fukuoka 830-0011, 
      Japan. suekane@med.kurume-u.ac.jp
FAU - Nishitani, Masaaki
AU  - Nishitani M
FAU - Noguchi, Masanori
AU  - Noguchi M
FAU - Komohara, Yoshihiro
AU  - Komohara Y
FAU - Kokubu, Takako
AU  - Kokubu T
FAU - Naitoh, Masayasu
AU  - Naitoh M
FAU - Honma, Shigenori
AU  - Honma S
FAU - Yamada, Akira
AU  - Yamada A
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Matsuoka, Kei
AU  - Matsuoka K
FAU - Kanayama, Hiroomi
AU  - Kanayama H
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071005
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Cancer Vaccines/*toxicity
MH  - Carcinoma, Renal Cell/*immunology/pathology
MH  - Combined Modality Therapy
MH  - Cytokines/therapeutic use
MH  - HLA-A Antigens/immunology
MH  - HLA-A2 Antigen/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Kidney Neoplasms/*immunology/pathology
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Patient Selection
MH  - Vaccines, Subunit/*toxicity
EDAT- 2007/10/09 09:00
MHDA- 2007/12/22 09:00
CRDT- 2007/10/09 09:00
PHST- 2007/10/09 09:00 [pubmed]
PHST- 2007/12/22 09:00 [medline]
PHST- 2007/10/09 09:00 [entrez]
AID - CAS631 [pii]
AID - 10.1111/j.1349-7006.2007.00631.x [doi]
PST - ppublish
SO  - Cancer Sci. 2007 Dec;98(12):1965-8. doi: 10.1111/j.1349-7006.2007.00631.x. Epub 
      2007 Oct 5.